Shandong Pharmaceutical Glass Co.Ltd Stocks

CN¥ 18.7Last Updated 15.04.2026

Issuer Rating

5/7
Performance

Average

Risk

Low

Recommendation

Hold

Market Cap

CN¥ 1.78B

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
CN¥ 18.7
Key Takeaways

Risk factor

Strong & resilient to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Shandong Pharmaceutical Glass Co., Ltd manufactures and sells pharmaceutical glass packaging and butyl rubber series products in China. It offers pharma glass packaging products, such as molded injection glass vials, food-grade bottles, clear cosmetic bottles, cobalt blue and green bottles, tubular glass vials, ampoules, glass tubing products, amber glass bottles, and other borosilicate glass products; butyl rubber stoppers; prefilled syringes, plastic and aluminum caps, plastic caps, and plastic bottles; and dropper caps and Teflon coated rubber stoppers. The company sells its products to the pharmaceutical, food, and cosmetic glass packaging industries. It also exports its products to Europe, the United States, Russia, Japan, Korea, Southeast Asia, and other countries. Shandong Pharmaceutical Glass Co., Ltd was founded in 1970 and is based in Zibo, China.

Company Valuation

Fairly valued
4/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers. In particular, the stock is reasonably priced on P/E, of fair value on E

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks